16results about "Cytochromes" patented technology

To provide recombinant adeno-associated viral vectors for treating Bietti Crystalline Dystrophy.SOLUTION: Provided are a recombinant adeno-associated vector comprising a codon-optimized sequence encoding CYP4 V2 linked to predetermine gene expression regulatory sequences, and its use in treating Bietti Crystalline Dystrophy (BCD).SELECTED DRAWING: None

The disclosure relates to transcription cassettes, expression vectors and microbial cells adapted for the expression of genes regulated by the RBA transcription factor.

The application discloses a method for efficiently labeling proteins with selenium, which comprises the following steps: adjusting the ratio of selenium and sulfur in the culture medium during the expression of a plasmid containing a target protein by a prokaryotic expression system, and realizing the efficient replacement of selenium atoms for the cysteine sulfur atoms in the target protein; under the premise of maintaining the good growth state of cells, the selenium labeling efficiency can reach 86%, and the protein expression amount is stably about 1 mg / g (protein / biomass wet weight); structure analysis shows that the obtained selenium labeled protein is basically consistent with the natural protein in the secondary structure and does not change obviously. The method is simple in operation, high in labeling efficiency and protein yield, good in repeatability, and suitable for structural biology research such as nuclear magnetic resonance, provides an effective means for studying the function mechanism of sulfur atoms in biological macromolecules (including small peptides, polypeptides, peptide segments, proteins, and complexes of proteins or peptides) by using selenium as a probe, and has good scientific research application prospect and industrialization popularization value.

A polypeptide comprising a residue substituted by a non-canonical amino acid (ncAA) is provided. Methods for: (a) transferring an electron to an electrode, by coupling the polypeptide to an electrode; and (b) quantifying the amount of an analyte e.g., glucose are also provided.

The invention belongs to the field of microbial metabolic engineering, and discloses recombinant saccharomyces cerevisiae for synthesizing p-coumaric acid by using acetic acid as well as a preparation method and application of the recombinant saccharomyces cerevisiae. The recombinant saccharomyces cerevisiae has the following characteristics that: tyrosine lyase FjTAL, phenylalanine lyase AtPAL2, cinnamic acid 4-hydroxylase AtC4H, cytochrome P450 reductase AtATR2 and cytochrome B5 CYB5 are subjected to overexpression. The invention also provides a construction method and a domestication method of the recombinant saccharomyces cerevisiae. Compared with recombinant saccharomyces cerevisiae which is not evolved, the recombinant saccharomyces cerevisiae evolved adaptively can well grow in a culture medium which takes acetic acid as a unique carbon source, and p-coumaric acid with higher yield can be synthesized. The invention provides a feasible strategy for synthesizing p-coumaric acid, flavonoid or stilbene natural products by using acetic acid as a carbon source.

The application discloses a new use of cytochrome C in preparing an ELISA kit and relates to the field of biotechnology. The application uses cytochrome C (Cytochrome c, CC) and streptavidin (Streptavidin, SA) to construct a fusion protein, and the fusion protein has a good detection effect in an ELISA experiment. The fusion protein can simplify a production process, reduce production cost and has a good market conversion prospect.

The present disclosure relates to recombinant engineered polypeptides with cytochrome P450 (CYP) activity capable of selectively catalyzing the conversion of precursor compounds, carvacrol and / or thymol, to the product compound, thymohydroquinone (THQ), and recombinant host cells that heterologously express genes encoding these polypeptides (e.g., in yeast) and that can be used for enhanced fermentative bioproduction of the product compound THQ.

The present invention relates to a method for treating, preventing, or reducing a disease or disorder, e.g., hypertension, in a subject in need thereof. In embodiments, the method comprises co-administering to the subject an effective amount of a cytochrome P4503A4 (CYP3A4) inhibitor, an effective amount of a nitric oxide (NO) potentiator, and an effective amount of a phosphodiesterase-5 (PDE5) inhibitor. In some embodiments, the CYP3A4 inhibitor and the NO potentiator are the same compound.

The application belongs to the technical field of metal organic framework (MOF) immobilized enzyme, and particularly relates to a method for wrapping enzyme by seed orientation and application thereof. The application discloses a method for synthesizing enzyme@MOF composite by seed orientation, and based on the characteristics of MOF crystal growth, the seed orientation synthesis method is innovatively proposed. The addition of seed can greatly promote the synthesis efficiency of enzyme@MOF composite and greatly increase the encapsulation efficiency of enzyme. Meanwhile, the seed orientation synthesis method has no requirement on the chemical properties of enzyme / protein, and does not need to destructively modify the enzyme / protein to improve the encapsulation efficiency, so that the seed orientation synthesis method has good universality. The seed orientation synthesis method solves the problems of low universality and low efficiency in the existing enzyme@MOF composite synthesis method, and has an expected application prospect in the fields of biological catalysis, biological sensing, biological medicine and the like.

Particles comprising a protein and optionally an activator, for example, particles comprising whey protein hydrolysate and optionally tryptophan, are described herein. Methods for preparing and using particles comprising a protein and optionally an activator are also described herein.

The application provides a CYBB lentivirus vector, a stem cell transfected by the lentivirus vector and a preparation method and application thereof. The lentivirus vector comprises an hEF1 alpha promoter and CYBB tandem co-expression. The lentivirus vector of the application carries a CYBB gene, realizes safe and efficient expression of the carried CYBB gene in differentiated or undifferentiated stem cells under the start of an hEF1 alpha promoter, and meanwhile, the stem cell serves as a potential delivery carrier, and the expression amount of the CYBB gene in a transgenic cell is improved.

A nanowire may be isolated from a bacterium, wherein the nanowire includes c-type heme subunits or pili proteins and is capable of establishing an electrical connection with an insoluble electron acceptor. The c-type heme subunits may comprise OmcS or OmcZ cytochrome subunits or any combination thereof. The pili proteins may have an amino acid sequence with at least one residue modified, from a wild-type strain of the microorganism, to include an aromatic amino acid. The nanowire may have metallic or semiconducting conductive properties, and may be integrated into an electronic device.